RNA interference (RNAi) is an evolutionarily conserved mechanism for sequence-specific target RNA degradation in animals and plants, which plays an essential role in gene regulation. In addition, it is believed to function as a defense against viruses and transposons. In recent years, RNAi has become a widely used approach for studying gene function by targeted cleavage of a specific RNA. Moreover, the technology has been developed as a new therapeutic option that has already made its way into clinical testing.
Introduction
well-known viruses, like the H1N1/09 influenza virus, cause pandemics of global dimensions. Thus, there is a pressing unmet medical need to develop new antiviral drugs. While small molecules have dominated antivirals for decades, biologics like monoclonal antibodies and nucleic acids therapies have more recently been considered promising alternatives (1) .
Among the various oligonucleotide-based strategies, RNA interference (RNAi) is widely regarded as a particularly powerful technology (2) (3) (4) . RNAi is a posttranscriptional gene silencing mechanism that is triggered by double-stranded RNA. For applications in mammalian cells, small interfering RNAs (siRNA) of approximately 19 base pairs with two nucleotide overhangs at the 3¢ ends of both strands become incorporated into the RNAinduced silencing complex (RISC) and induce cleavage of a complementary target RNA. Within just a few years, RNAi has become a standard molecular biological method to study gene functions. Moreover, the technology has been developed into a new therapeutic approach and approximately a dozen clinical trials based on RNAi are currently underway. Among these trials are various applications of RNAi to treat infections with the respiratory syncytial virus, HBV and HIV (5) .
Silencing of endogenously expressed genes has become a routine procedure and predesigned or validated siRNAs with silencing guarantee against virtually any human or murine gene are commercially available. In contrast, the design of siRNAs with high antiviral activity still remains a challenging task. Several features have been described that influence the success of an RNAi approach (6):
Thermodynamic design of the siRNA.
• •
Structure of the siRNA antisense strand.
Structure of the target RNA.
Most of the publically available tools for the design of siRNAs exclusively optimize the base composition of the siRNA. More recently, however, a design algorithm was developed for the selection of siRNA with particularly high potency and specificity, which not only focuses on the design of the siRNA, but also takes into consideration the secondary structures of the siRNA and their target site (7) .
A major challenge for the long-term inhibition of viruses by RNAi is the prevention of viral escape. Thus, siRNAs need to be directed against well-conserved target sites. Unfortunately, simply directing siRNAs to protein coding regions is insufficient, since silent mutations can cause the siRNAs to lose their inhibitory potential. Target regions with an important function in the structure of the RNA may prove to be a better choice to avoid viral escape. It has, for example, been shown that an siRNA against the highly conserved cis-acting replication element (CRE) was capable of inhibiting various enteroviruses over a long period, while an siRNA targeted against protein-encoding regions of the RNA, which are not organized into functional three dimensional structures, led to rapid viral escape (8) . Since even the most careful selection of a single target site might be insufficient for sustained viral silencing, use of multiple siRNAs against multiple target sites may be necessary to prevent viral escape. In the case of coxsackievirus B3 and HIV-1, resistance rapidly emerged when single molecules were used, but a combination of three or four siRNAs, respectively, targeting distinct regions of the genome, were able to prevent the emergence of resistance (9, 10) .
A general requirement for the application of RNAi in vivo is the stabilization of siRNAs by the introduction of modified nucleotides (11) . Based on the experience in the antisense field, numerous modified nucleotides have been assessed for their applicability to enhance the stability of siRNAs against nucleases. Phosphorothioates, nucleotides with modifications at the 2¢ position (e.g., 2¢-O-methyl-RNA and 2¢-fluoro-nucleotides), as well as locked nucleic acids are among the most widely employed building blocks for RNAi applications. A fully modified siRNA with a drastically increased half-life in human serum had a significantly higher activity in a vector-based in vivo model of HBV infection as compared to the unmodified form (12) . Furthermore, the introduction of modified nucleotides not only improves the stability of siRNAs, but can also reduce off-target effects (13) and improves the antiviral activity of siRNAs directed against highly structured target regions (14) .
The present chapter describes a systematic method for the design of highly potent antiviral siRNAs (summarized in Fig. 1 ). Experimental procedures to test these siRNAs in reporter assays (GFP Reporter Assay and Dual-Luciferase Reporter Assay) as well as in assays with infectious viruses (Cell viability assay and Plaque reduction assay) will be outlined. Finally, options to improve the properties of siRNAs by introduction of modified nucleotides will be described. 10. Chemiluminescence Imager or material for wet development inclusive X-ray films.
Materials for reverse transcription
1. The first major step for the design of highly active siRNAs consists of the selection of siRNA sequences with favorable thermodynamic features. The thermal stability of both ends, as well as base preferences of active siRNAs at certain positions, influence the silencing efficiency of an siRNA (15) . For the design of siRNAs, publically available web tools are used (examples are given in Table 1 ). It is advisable to generate an siRNA pool with at least two different web tools. The BLAST option should be applied to avoid unspecific binding to endogenous target sequences, thereby reducing off-target effects. As an example, siRNA predesign using RNAi Designer from Invitrogen is described below:
(a) Go to the RNAi Designer website from Invitrogen (see Table 1 ).
(b) Choose siRNA as "Target Design Options."
(c) Enter the complete or partial target sequence. Use highly conserved regions of the virus (see Note 1).
(d) Deselect all options for target region selection (ORF, UTR). (f) "GC content" should be set to a minimum of 25% and a maximum of 55%.
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(g) Select default motif pattern (see Note 2).
(h) Submit by pressing the RNAi Design button. A summary of designed siRNAs is given in a new window. Sort the output by choosing ranking.
(i) Select siRNAs with 4½ to 5 stars and copy the sequences.
In general, choose the best siRNAs obtained with a design tool. If the siRNA design tool did not include a BLAST option, an NCBI BLAST should follow (see Note 3).
2. The obtained siRNA pool is subsequently filtered with respect to their thermodynamic features:
(a) Convert all sequences to obtain the antisense strand of each siRNA in a 5¢ to 3¢ orientation. Antisense strands are complementary to their target RNA (see Fig. 2 ).
(b) Remove duplicate siRNAs. Only 100% identical siRNA sequences should be excluded since a single nucleotide shift can sometimes influence the efficiency of an siRNA.
(c) Calculate the score of each siRNA based on the scoring system given in Table 2 .
(d) Exclude siRNAs that have less than 6 points of Reynolds' criteria.
3. The second major step is to exclude siRNAs whose antisense strand is predicted to form secondary structures. To this end, the change in Gibbs free energy (DG) of the siRNA antisense strand is determined. Negative DG values indicate stable secondary structures, whereas positive DG values indicate instable secondary structures resulting in a high degree of unfolded single-stranded RNA. The DG determination using the publically available UNAfold software is described. This software extended and replaced the mfold software of Zuker (16) .
(a) Go to the Rensselaer bioinformatics web server (see Table 3 ) and use the DINAMelt Web Server.
(b) Select the application Nucleic Acid Quikfold. (d) Choose RNA (3.0) in the "energy rules" field. The RNA is now folded at the fixed temperature of 37°C. The hybridization temperature can be modified by using RNA (2.3). Additionally, "sequence type" has to be specified as linear. Other settings in this window are not necessary.
(e) Submit to DINAMelt Server. A summary of potential folding results is given in a new window (see Note 4) . Exclude all siRNAs whose antisense strand is predicted to form secondary structures indicated by at least one structure with a negative DG value. Structures with DG values around zero have a folding probability of 0.5 (17) and should be further analyzed (see Note 5).
4. The accessibility of the target RNA sequence will be considered in the third major step of siRNA design. The procedure consists of two steps: First, folding of the entire target RNA molecule and, second, the determination of the change in Gibbs free energy (DG) of the local RNA target site. DG determination using the publically available mfold3.2 software, which should be used preferentially for long RNA sequences, is subsequently described (16) .
(a) Go to the "Rensselaer bioinformatics web server" (see Table 3 ) and use the Mfold Web Server.
(b) Select the application RNAfold.
(c) Enter the "name" and the "sequence" to be folded.
(d) Choose "RNA sequence is" linear. The folding temperature is fixed at 37°C. This temperature can be modified by using the RNA mfold version 2.3 server. The "upper bond on the number of computing folding" can be limited to 10 or less for long sequences as they may increase the computational load and resulting response time.
Other settings in this window are not necessary.
(e) Sequences shorter than 800 bases can be folded immediately (as of March 2010). For longer RNA sequences up to 6,000 bases, select batch and enter your E-mail address.
(f) Submit your entries by pressing the Fold RNA button. RNA sequences longer than 6,000 bases can be folded by the alternative "Burnet Institute mfold Server" (see Table 3 ). The application Submit a RNA sequence is based on mfold version 3.0. Parameters in this window can be set according to the mfold version 3.2 described above, except the folding temperature, which is not fixed at 37°C. Additionally, limit the "upper bond on the number of computing folding" to 10. Both "Rensselaer bioinformatics web server" and "Burnet Institute mfold Server" will give a summary of potential folding results.
(g) DG is calculated for a number of potential secondary structures (listed as "Structure 1, 2, 3 …" beneath "View Individual Structures"). The more negative DG, the more stable secondary structure is going to be, which also indicate a higher chance of its presence in a biological system.
(h) Save at least ten structures using the Download all foldings button.
(i) Find the corresponding target structures of the siRNAs in every potential folding.
(j) Select the most promising siRNA target sites by checking the following points:
(i) Number of identical or similar target sites. The program will give various structures and corresponding energies (DG). Good target accessibility in different structure predictions increases the possibility of overall target accessibility.
(ii) Number of bonds. High number of bonds (base pairs) within the target sequence indicates a strong secondary structure and less accessibility for an siRNA.
(k) Determine the DG value of the local RNA target structure for the selected siRNA target sites:
(i) Find the corresponding siRNA target site and determine all bases within the target site that are involved in forming a secondary structure. Add also bases or base pairs which are part of the close neighborhood, for example bases that form loops, even if these are not part of the siRNA target site.
(ii) Go to Thermodynamic Details of chosen structure in the Output window (folding results).
(iii) Find the corresponding bases (marked by numbers) and add all single DG values of involved bases. Energies of helices and loops have to be included if one base of this structure is part of the target site. This calculation results in an approximation of DG local which is usually sufficient. If precise calculation of DG local is necessary, please refer to the Turner energy rules ( Table 3 ).
(iv) Calculate the change in Gibbs free energy (DG) of all local RNA target structures (DG local ). Exclude all siRNAs whose target structure showed strong variability based on at least ten folded structures (³5 different target structures). Furthermore, accessible target sites are characterized by low DG local values (18) . Therefore, select siRNAs in the order of their DG local values with a threshold of about −15 kcal/ mol (19) . The selected siRNAs are potentially efficient siRNAs and their silencing efficiency can further be tested in Reporter Assays (see Subheading 3.2 and Note 6).
Reporter assays are the method of choice to verify the efficiency of the selected siRNAs. The virus target sequence is cloned upstream or downstream of a GFP or luciferase reporter and is then cotransfected with the selected siRNAs. The virus target sequence, which is a partial viral sequence, should be long enough to simulate the structural environment of siRNA target sequence (20) . In contrast, very long sequences may complicate reverse transcription and/or PCR amplification of the viral target sequence and may negatively influence the transfection efficiency of eukaryotic cells (see Note 7) .
The protocol for TOPO cloning described in the following section is a shortened version of the instruction manual (see Note 8) .
The TOPO cloning allows the ligation of the PCR-amplified target sequence of the virus into either pcDNA3.1/CT-GFP-TOPO or pcDNA3.1/NT-GFP-TOPO. The terms CT and NT indicate that GFP will be expressed fused to, respectively, the C-terminus and N-terminus of the target sequence. (G or A)NNATGG (N = any base)) needs to be incorporated into the forward primer. The PCR product for pcDNA3.1/ NT-GFP-TOPO may also be cloned in frame with GFP, but this is not essential if a translational stop codon is introduced upstream of the virus target sequence. We observed an improved GFP expression using this modified reporter 25. To verify the orientation of the insert, analyze the plasmids by restriction analysis. To this end, it is advantageous to use at least one restriction site located within the virus target sequence and one that is present in the vector (see Note 12) .
In Vitro Testing: Reporter Assays
26. Clones containing inserts in the correct orientation should be sequenced to confirm that the original sequence has not been mutated (see Subheading 2.1, items 8 and 9).
27. Culture the clone of choice in 200 ml LB medium containing 100 mg/ml ampicillin.
28. Isolate the plasmid DNA. Plasmid DNA for transfection into eukaryotic cells must be very clean and free from phenol and sodium chloride to prevent cell death and to avoid low transfection efficiencies.
The Dual-Luciferase Reporter Assay is a method to measure the activity of both firefly and Renilla luciferases in one sample. The virus target sequence is cloned in the 3¢ untranslated region (3¢-UTR) of the Renilla luciferase gene. In-frame cloning is not required as the translational stop codon of Renilla luciferase is present in psiCHECK-2 vector (cloning of the virus target sequence into this vector is subsequently described). The firefly luciferase, which is also expressed by the psi-CHECK-2 vector, allows normalization of the Renilla luciferase activity.
1. Isolate the virus DNA or RNA using commercially available DNA or RNA virus isolation kit.
Perform a Reverse Transcription reaction if the isolated virus
is based on RNA.
3. As in-frame cloning with Renilla luciferase gene is not required, the design of PCR primers follows common rules. Both primers contain one restriction site that is used for cloning into psiCHECK-2 vector (see Note 13) . For example, use: 9. Place the tube on ice.
10. Ligate the DNA fragment into the psiCHECK-2 vector that was previously digested with Not I and Xho I using a standard protocol.
11. Transform the ligation reaction into E. coli cells and analyze colonies as described in Subheading 3.2.1, steps 12-28.
Clones containing inserts in the correct orientation should be sequenced (see Subheading 2.2, item 5).
For a first functional assay of the siRNAs in a reporter assay, it is advisable to use the cell line which will also be employed for virus assays. As an example, a protocol for transient transfection of HeLa cells in 24-well plates using Lipofectamine 2000 transfection reagent will be described (see Note 14) . The transfection efficiency into other cell lines can be tested by transfection of a random siRNA that is labeled with Cy3 at the 5¢ end of the siRNA sense strand (siRNA can be transfected with or without a reporter plasmid). We recommend the use of Cy3, as FITC is not distinguishable from GFP in fluorescence microscopy.
1. Seed 5 × 10 4 HeLa cells per well in a volume of 500 ml medium without antibiotics.
2. Incubate overnight at 37°C and 5% CO 2 .
3. Dilute 0.8 mg of the reporter plasmid (pcDNA3.1/NT-GFP-TOPO, pcDNA3.1/CT-GFP-TOPO or psiCHECK-2 with inserted virus target sequence) and 10 nM of siRNA (designed antiviral siRNA or a negative control siRNA with no matches either to the viral or target organism genome) in Opti-MEM or serum-free medium to a total volume of 50 ml. The molar concentrations are related to the final volume of 600 ml.
Premix 2 ml of Lipofectamine 2000 transfection reagent with
48 ml Opti-MEM. 5 . Incubate for 5 min at room temperature. 6 . Combine Lipofectamine and DNA/siRNA mixture and incubate for at least 20 min. If one of the TOPO vectors described above served as a reporter in cotransfection with siRNAs (see Subheading 3.3), the first analysis of siRNA silencing efficiency can be performed using fluorescence microscopy. This requires a filter for GFP detection. After replacement of medium from the transfected culture cells with 500 ml PBS, GFP expression of the reporter plasmid is determined (see Fig. 3 ). Highly efficient siRNAs strongly reduce GFP expression compared to the transfection of reporter plasmid without an siRNA, while the control siRNA should have no effect. These results should be confirmed by Western Blot analysis as described in Subheading 3.4.1. In the case of psiCHECK-2 cotransfection, both Renilla and Firefly luciferases will be measured (see Subheading 3.4.2).
Cellular Assays: Transfection of Mammalian Cells
1. Remove the medium from the culture cells.
2. Wash the cells with 500 ml of PBS.
3. Remove PBS by aspiration.
4. Add 30 ml of DTT lysis buffer per well and transfer the lysate to an eppendorf tube.
5. Boil the lysate for 5 min at 95°C. Select efficient siRNAs for the following functional analysis in virus assay. Highly potent antiviral siRNAs reduce the GFP expression virtually to completion (Western Blot) or show at least 80% inhibition of Renilla luciferase (Dual-Luciferase Reporter Assay).
Analysis of siRNA Silencing Efficiency
Western Blot
A crucial test is the evaluation of the antiviral activity of designed siRNAs in assays with infectious virus. Two methods for in vitro testing are described below. The cell viability assay is an indirect method to quantify the efficiency of an siRNA, whereas the plaque reduction assay can show the direct inhibition of virus replication by an siRNA.
The XTT-based cell viability assay is used for the quantification of cell proliferation and viability. Metabolically active cells cleave the yellow tetrazolium salt to an orange formazan dye. The absorbance measured at a defined wavelength directly correlates with cell viability. We recommend the use of the XTT reagent due to its high sensitivity compared to other tetrazolium salts, such as MTT.
Virus Assays: Functional Analysis
Cell Viability Assay
1. Seed 2-3 × 10 4 HeLa cells per well in a volume of 100 ml medium without antibiotics in a 96 well plate.
2. Incubate overnight at 37°C and 5% CO 2 . Prepare the following siRNA transfection mixtures in quadruplicate.
3. Dilute siRNA (designed antiviral siRNA or a negative control siRNA with no matches either to the viral or target organism genome) in Opti-MEM or serum-free medium to a volume of 25 ml. The molar concentrations are related to the final volume of 150 ml. 11. Incubate at 37°C for 5 min before adding to the cells. Virus dilutions can be stored at 4°C for several minutes, if necessary.
12. Add 50 ml per well of the diluted virus suspension. Include negative control wells that remain uninfected. To this end, use serum-free medium without antibiotics and handle these cells identical to infected cells. 13 . Incubate for 30 min at 37°C and 5% CO 2 (see Note 20).
14.
Remove the virus suspension and add 100 ml of medium containing FCS and antibiotics.
15. Incubate at 37°C and 5% CO 2 until beginning the cell viability assay (XTT measurement). 16 . Prepare an adequate amount of XTT reagent. For example, mix 100 ml electron-coupling reagent with 5 ml XTT labeling reagent.
17. Add 50 ml per well of fresh XTT reagent and incubate 4 h at 37°C and 5% CO 2 . Do not remove the medium.
18. Measure the absorbance in a microtiter plate reader at a defined wavelength between 450 and 500 nm. The reference wavelength should be greater than 650 nm.
Generally, each plaque has its origin in the viral infection of a single cell. The reduction of virus titer shows directly the efficiency of an siRNA as the virus spread is prevented.
1. Seed 1.5-2.5 × 10 5 HeLa cells per well in a volume of 500 ml of medium without antibiotics in a 24 well plate.
3. Dilute siRNA (designed antiviral siRNA or a negative control siRNA with no matches either to the viral or target organism genome) in Opti-MEM or serum-free medium to a volume of 50 ml. The molar concentrations are related to the final volume of 600 ml. Prepare as many siRNA transfected wells as needed to titrate the different virus dilutions. Include positive control wells which remain untransfected, but will be infected with different virus dilutions.
Premix 2 ml of Lipofectamine 2000 transfection reagent with
48 ml Opti-MEM. 5 . Incubated for 5 min at room temperature.
6. Combine Lipofectamine and siRNA and incubate for at least 20 min.
7. Add the final mix (100 ml per well) to the cells. 8 . Incubate for at least 4 h at 37°C and 5% CO 2 (see Note 17) . Cells should be close to 100% confluent before overlaying the infected cell monolayer. 9. Prepare serial 1:10 dilutions of the virus stock in refrigeratorcold serum-free medium without antibiotics (see Note 19) . In general, an appropriate range of dilutions is 10 −4 to 10 −7 (depending on the titer of virus stock). = × pfu/ml counted plaques / (dilution factor volume of diluted virus added to the well).
An alternative protocol can be used to accelerate the staining (see Note 22) . Efficient siRNAs are able to reduce the virus titer at least one order of magnitude. Figure 4 shows an example of such a plaque reduction assay. Selected (antiviral) siRNAs which show high efficiency may be chemically modified to decrease potential off-target effects and/ or to enhance serum stability. One approach to reduce off-target effects is to prevent the incorporation of the unwanted sense strand in RISC. This can, for example, be achieved by an LNA modification at the 5¢ end (21) , or by introduction of a 2¢-O-methyl modification at position 1 and 2 (13) of the sense strand. However, a specific reduction of off-target effects was observed when position 2 of the antisense strand was additional 2¢-O-methyl modified (13) . In theory, chemical modifications of an siRNA will also result in increased serum stability. In practice, siRNA modifications are often accompanied by decreased silencing efficiency compared to the unmodified siRNA. LNA modifications introduced at any position except 1, 10, 12, and 14 in the antisense strand do not cause substantial loss of silencing efficiency (21) . Another way to combine high silencing efficiency, increased serum stability, and reduced off-target effects is complete modification
Chemical Modification: Generating Stabilized siRNAs
with different nucleotide analogs as shown for an siRNA targeting the HBV genome (12) (Fig. 5 ). However, chemical modifications are dependent on the application as well as on the virus to be inhibited.
With the strategy described here, it will be possible to identify efficient siRNAs against virtually any given virus -as we have recently exemplified for echovirus 30 (22) . The next step will be to transfer the antiviral RNAi approach to an in vivo model. One of the main challenges will then be efficient delivery of the siRNA to the desired target tissue. The following chapters describe virusbased approaches to deliver shRNA expression cassettes as well as different strategies for the application of chemically presynthesized siRNAs.
1. In order to identify conserved regions in the viral genome, it is advisable to select sequences of various strains and perform a BLAST search. Regions with high homology can be considered conserved and represent suitable siRNA target sites.
2. Tuschl's motif pattern strongly restricts the number of siRNAs for subsequent selection, which may become a problem if short sequences are targeted. 3. The NCBI BLAST tool or/and the Ensembl BLAST tool can be used for homology searches (see Table 3 ).
Notes
4. If the summary of potential folding is: "No folding possible" and/or the software are/is showing the term ∞ for DG, then the RNA sequence does not form any secondary structure.
5. If all siRNAs (antisense strand) give negative DG values, examine all structures again and use only siRNAs that show stem-loop structures with ³2 nucleotide free at the 5¢ terminus and ³4 free nucleotides at the 3¢ terminus for further analyses (17).
6. If no siRNAs meet the indicated criteria, first check if another partial sequence of the virus can be targeted. Alternatively, the threshold for DG of the local RNA target site can be adjusted, especially if many siRNAs remain whose antisense strands do not form stable secondary structures (see also Note 5) . To this end, select at least four siRNAs in order of their DG local values. The threshold of Reynolds' criteria should not be changed.
7.
In general, it is best to include a partial target RNA with a length of 1-2 kb that spans the siRNA target sequence.
8. Both an extended protocol and a trouble shouting guide of TOPO cloning can be found in the complete instruction manual provided with the kit. 9. For long virus target sequences, use a polymerase with proofreading activity. Since the amplified sequences will lack 3¢ A-overhangs, which are essential for the described cloning method, additional incubation with Taq polymerase is necessary.
10. If E. coli is to be transformed by electroporation, the salt solution must be diluted fourfold to a final concentration of 50 mM NaCl and 2.5 mM MgCl 2 to prevent arcing.
11. Optionally, 1.5 ml of 1.42 mM b-mercaptoethanol can be added to the chemically competent E. coli cells followed by an incubation on ice for 20 min. This procedure may increase the transformation efficiency. Store the 1.42 mM solution of b-mercaptoethanol at 4°C.
12.
Vector maps and sequences of pcDNA3.1/CT-GFP-TOPO and pcDNA3.1/NT-GFP-TOPO are available on the Invitrogen website (see Table 3 ). Vector map and sequence of psiCHECK-2 is available on the Promega website (see Table 3 ).
13. Other restriction sites may also be suitable. In this case, customize the additional bases for efficient restriction and the incubation time. An extensive table is provided by New England Biolabs (see Table 3 ).
14. The use of other cell lines or/and other transfection reagents will require different conditions than those given here. 15 . Density of SDS-polyacrylamide gel depends on molecular weight (MW) of the target sequence. If pcDNA3.1/CT-GFP-TOPO was used, add the MW of GFP (around 15 kD) to the calculated MW of the target sequence for an estimate, though some sequences may influence gel mobility, leading to measured weights other than the predicted value. 16 . LARII aliquots have to be thawed at room temperature, as the reagent is heat-labile.
17. Incubation overnight is also possible if the cells are plated at a lower density.
18. An m.o.i. of 0.1 is suitable for many viruses, but in some cases may need to be adjusted. The control infection should show as many individual plaques as can be reliably counted. An effective siRNA will appreciably reduce the number of plaques, while a weak siRNA may only lead to a slight reduction. A large number of distinguishable plaques on the control plate will simplify the recognition of weak siRNAs, which may be desirable if further optimization is possible. 19 . FCS within a medium may interfere with viral infection efficiency.
20. Incubation time depends on the infection cycle of a specific virus. 21 . Neutral red as well as crystal violet is taken up by healthy cells, but not by dead cells. Plaques therefore appear as clear circles against the red/violet background. If the clear areas overlap too much, it is difficult to recognize individual plaques and infection time should be reduced. If plaques are too small to be easily read, try extending infection time, though it could also be an indication of a defective or weakened strain. 22 . The staining can be accelerated by using crystal violet solution. To this end, fix the cells with 10% TCA for 10 min at room temperature. Then remove the agar without disturbing the cell monolayer and add 500 ml of crystal violet solution (0.5% solution in PBS) to each of the wells and incubate for 5 min at room temperature (see Note 21) . Remove the stain by aspiration and wash with PBS. Invert the plate, and count the plaques of each well. Calculate the viral titer as described in Subheading 3.5.2, step 22.
